NAUT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nautilus Biotechnology Inc (NAUT) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While there are some positive catalysts such as insider and hedge fund buying, the company's financial performance remains weak, and technical indicators do not suggest a clear upward trend. Additionally, there are no strong trading signals or recent news to support an immediate buy decision.
The technical indicators are neutral to slightly bearish. The MACD histogram is below zero and negatively contracting, RSI is neutral at 47.451, and moving averages are converging. Key support is at 2.899, and resistance is at 3.387. The stock does not show strong momentum for a breakout.
Hedge funds and insiders are significantly increasing their buying activity, with hedge fund buying up by 499,900% and insider buying up by 994.6% in recent periods. Analysts have raised the price target to $4 and maintained a Buy rating.
There is no recent news or event-driven catalyst to support a strong upward move.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income drop to -$13.78 million (-21.67% YoY), and a decline in EPS to -0.11 (-21.43% YoY). Gross margin remains at 0%.
Guggenheim raised the price target from $2.50 to $4 and maintained a Buy rating, citing a modest line of sight to revenue in 2027. However, the revenue outlook remains limited in the near term.
